Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5729-5732

  Parsons, Joshua B ^a   Frank, Matthew W ^a   Rosch, Jason W ^a   Rock, Charles O ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; FATTY ACID; FATTY ACID SYNTHASE INHIBITOR; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; THIOCTIC ACID; UNSATURATED FATTY ACID;

ADDITION REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; AUXOTROPHY; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; IN VITRO STUDY; MAMMAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS;

ACETYL-COA CARBOXYLASE; ANIMALS; ANTI-BACTERIAL AGENTS; FATTY ACID SYNTHESIS INHIBITORS; FATTY ACIDS; GENE DELETION; MICE; MICROBIAL VIABILITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84885916527     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01038-13     Document Type: Article

References (27)

1. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. 2006. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368:874-885.
2. Parsons JB, Rock CO. 2011. Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr. Opin. Microbiol. 14:544-549.
3. Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. 2011. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc. Natl. Acad. Sci. U. S. A. 108: 15378-15383.
4. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. 2009. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458:83-86.
5. Kaplan N, Awrey D, Bardouniotis E, Berman J, Yethon J, Pauls HW, Hafkin B. 2013. In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics. J. Chemother. 25:18-25.
6. Banevicius MA, Kaplan N, Hafkin B, Nicolau DP. 2013. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J. Chemother. 25:26-31.
7. Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, Dorsey M, Hafkin B, Ramnauth J, Romanov V, Schmid MB, Thalakada R, Yethon J, Pauls HW. 2012. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob. Agents Chemother. 56:5865-5874.
8. Cronan JE, Jr, Waldrop GL. 2002. Multi-subunit acetyl-CoA carboxylases. Prog. Lipid Res. 41:407-435.
9. Lacks S, Hotchkiss RD. 1960. A study of the genetic material determining an enzyme in Pneumococcus. Biochim. Biophys. Acta 39:508-518.
10. Morris TW, Reed KE, Cronan JE, Jr. 1994. Identification of the gene encoding lipoate-protein ligase A of Escherichia coli. Molecular cloning and characterization of the lplA gene and gene product. J. Biol. Chem. 269:16091-16100.
11. Martin N, Christensen QH, Mansilla MC, Cronan JE, de Mendoza D. 2011. A novel two-gene requirement for the octanoyltransfer reaction of Bacillus subtilis lipoic acid biosynthesis. Mol. Microbiol. 80:335-349.
12. Shimomura Y, Sugiyama S, Takamura T, Kondo T, Ozawa T. 1986. Quantitative determination of the fatty acid composition of human serum lipids by high-performance liquid chromatography. J. Chromatogr. 383: 9-17.
13. Kreiswirth BN, Lofdahl S, Betley MJ, O'Reilly M, Schlievert PM, Bergdoll MS, Novick RP. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305:709-712.
14. Schwan WR, Wetzel KJ, Gomez TS, Stiles MA, Beitlich BD, Grunwald S. 2004. Low-proline environments impair growth, proline transport and in vivo survival of Staphylococcus aureus strain-specific putP mutants. Microbiology 150:1055-1061.
15. Buzzola FR, Barbagelata MS, Caccuri RL, Sordelli DO. 2006. Attenuation and persistence of and ability to induce protective immunity to a Staphylococcus aureus aroA mutant in mice. Infect. Immun. 74:3498-3506.
16. Yao J, Zhong J, Fang Y, Geisinger E, Novick RP, Lambowitz AM. 2006. Use of targetrons to disrupt essential and nonessential genes in Staphylococcus aureus reveals temperature sensitivity of Ll.LtrB group II intron splicing. RNA 12:1271-1281.
17. Sloane V, Blanchard CZ, Guillot F, Waldrop GL. 2001. Site-directed mutagenesis of ATP binding residues of biotin carboxylase: insight into the mechanism of catalysis. J. Biol. Chem. 276:24991-24996.
18. Zhang Y-M, Rock CO. 2008. Membrane lipid homeostasis in bacteria. Nat. Rev. Microbiol. 6:222-233.
19. Rangan KJ, Yang YY, Charron G, Hang HC. 2010. Rapid visualization and large-scale profiling of bacterial lipoproteins with chemical reporters. J. Am. Chem. Soc. 132:10628-10629.
20. Stoll H, Dengjel J, Nerz C, Gotz F. 2005. Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect. Immun. 73:2411-2423.
21. Freiberg C, Pohlmann J, Nell PG, Endermann R, Schuhmacher J, Newton B, Otteneder M, Lampe T, Habich D, Ziegelbauer K. 2006. Novel bacterial acetyl-coenzyme A carboxylase inhibitors with antibiotic efficacy in vivo. Antimicrob. Agents Chemother. 50:2707-2712.
22. Parsons JB, Kukula M, Jackson P, Pulse M, Simecka JW, Valtierra D, Weiss WJ, Kaplan N, Rock CO. 2013. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob. Agents Chemother. 57:2182-2190.
23. Miyakawa S, Suzuki K, Noto T, Harada Y, Okazaki H. 1982. Thiolactomycin a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice. J. Antibiot. (Tokyo) 35:411-419.
24. Balemans W, Lounis N, Gilissen R, Guillemont J, Simmen K, Andries K, Koul A. 2010. Essentiality of FASII pathway for Staphylococcus aureus. Nature 463:E3. doi:10.1038/nature08667.
25. Wang J, Kodali S, Lee SH, Galgoci A, Painter R, Dorso K, Racine F, Motyl M, Hernandez L, Tinney E, Colletti SL, Herath K, Cummings R, Salazar O, Gonzalez I, Basilio A, Vicente F, Genilloud O, Pelaez F, Jayasuriya H, Young K, Cully DF, Singh SB. 2007. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl. Acad. Sci. U. S. A. 104:7612-7616.
26. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang YS, Cummings R, Ha S, Dorso K, Motyl M, Jayasuriya H, Ondeyka J, Herath K, Zhang C, Hernandez L, Allocco J, Basilio A, Tormo JR, Genilloud O, Vicente F, Pelaez F, Colwell L, Lee SH, Michael B, Felcetto T, Gill C, Silver LL, Hermes JD, Bartizal K, Barrett J, Schmatz D, Becker JW, Cully D, Singh SB. 2006. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441:358-361.
27. Fattom AI, Sarwar J, Ortiz A, Naso R. 1996. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 64:1659-1665.